Elicio Therapeutics (NASDAQ:ELTX) vs. Zenas BioPharma (NASDAQ:ZBIO) Head-To-Head Comparison

Zenas BioPharma (NASDAQ:ZBIO) and Elicio Therapeutics (NASDAQ:ELTX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, analyst recommendations, earnings, valuation and profitability.

Profitability

This table compares Zenas BioPharma and Elicio Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Zenas BioPharma	N/A	-112.13%	-76.14%
Elicio Therapeutics	N/A	-2,748.16%	-151.12%

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Zenas BioPharma and Elicio Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zenas BioPharma	2	1	6	0	2.44
Elicio Therapeutics	1	0	2	1	2.75

Zenas BioPharma currently has a consensus price target of $44.29, suggesting a potential upside of 134.32%. Elicio Therapeutics has a consensus price target of $18.00, suggesting a potential upside of 65.14%. Given Zenas BioPharma’s higher possible upside, equities research analysts plainly believe Zenas BioPharma is more favorable than Elicio Therapeutics.

Earnings & Valuation

This table compares Zenas BioPharma and Elicio Therapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zenas BioPharma	$10.00 million	108.43	-$377.74 million	($7.81)	-2.42
Elicio Therapeutics	N/A	N/A	-$39.57 million	($2.40)	-4.54

Elicio Therapeutics has lower revenue, but higher earnings than Zenas BioPharma. Elicio Therapeutics is trading at a lower price-to-earnings ratio than Zenas BioPharma, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

35.0% of Elicio Therapeutics shares are owned by institutional investors. 22.0% of Zenas BioPharma shares are owned by insiders. Comparatively, 50.9% of Elicio Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Risk & Volatility

Zenas BioPharma has a beta of -0.61, meaning that its stock price is 161% less volatile than the S&P 500. Comparatively, Elicio Therapeutics has a beta of 1.12, meaning that its stock price is 12% more volatile than the S&P 500.

Summary

Elicio Therapeutics beats Zenas BioPharma on 7 of the 13 factors compared between the two stocks.

About Zenas BioPharma

Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.

About Elicio Therapeutics

Angion Biomedica Corp. is a late-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Angion Biomedica Corp. is based in UNIONDALE, N.Y.